AI TRENDS | Insilico Medicine to Join Hang Seng Biotech Index

Insilico Medicine (03696.HK) announced that it will be included in the Hang Seng Biotech Index, according to Jin10. This inclusion follows the results of the Hang Seng Index Company's review for the first quarter of 2026. The change will be implemented after the market closes on June 5, 2026, and will take effect on June 8, 2026. The Hang Seng Biotech Index aims to reflect the overall performance of the largest 30 biotech companies listed in Hong Kong that also qualify for the Stock Connect program. The board of directors believes that this inclusion demonstrates the capital market's recognition and confidence in the company's long-term development potential, which will help expand the investor base and enhance trading liquidity.